Alaska Medicaid

DICLEGIS®, Bonjesta® (doxylamine succinate and pyridoxine hcl)

Available Delayed Released tablets

INDICATIONS and USAGE:

DICLEGIS is a fixed dose combination drug product of 10 mg doxylamine succinate, an antihistamine, and 10 mg pyridoxine hydrochloride, a Vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. BONJESTA is a fixed dose combination drug product of 20 mg doxylamine succinate, an antihistamine, and 20 mg pyridoxine hydrochloride, a Vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Limitations of Use
DICLEGIS and BONJESTA are contraindicated with concurrent use of MAO inhibitors.

Criteria for Approval:

1. Diagnosis from the 'Indication and Usage' section; **AND**
2. Documented trial and failure of at least one conservative management regimen for nausea and vomiting.

Length of Authorization:

Coverage may be approved for 3 months.

Quantity Limit:

Diclegis – 120 tablets per 30 days
Bonjesta – 60 tablets per 30 days

Reminder: You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088

References:

Diclegis® [Package Insert] Bryn Mawr, PA; Duchesnay Inc.; May 2013.

Bonjesta® [Package Insert] Bryn Mawr, PA; Duchesnay Inc.; June 2018.

Diclegis criteria
Version 2
Original: 1/02/2014
Last updated 4/15/2022
Approved 4/15/2022